RecruitingRecruiting
Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
NCT07871409 · Amgen
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 3 Multicenter, Open-label, Single-arm Trial Evaluating Home Self-Administration of Subcutaneous Maridebart Cafraglutide Via Autoinjector in Adult Participants Living With Obesity or Overweight Without Type 2 Diabetes Mellitus
About this study
The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.
Eligibility criteria
Inclusion Criteria:
* Body mass index (BMI) ≥ 30 kilograms per meter square (kg/m\^2), or BMI ≥ 27 to \< 30 kg/m\^2 with one of the following:
* hypertension: treated, or with systolic blood pressure ≥ 130 millimeters of mercury (mmHg) or diastolic blood pressure ≥ 80 mmHg
* dyslipidemia: treated or previously diagnosed high cholesterol, high triglycerides, or low HDL cholesterol.
* history of obstructive sleep apnea
* history of cardiovascular disease
* history of fatty liver disease (including metabolic dysfunction-associated steatotic liver disease \[MASLD\] or metabolic dysfunction-associated steatohepatitis \[MASH\])
* At least 1 unsuccessful attempt at weight loss by diet and exercise.
* Contraception for females.
* Willingness to follow trial procedures for the duration of the trial.
Exclusion Criteria:
* Obesity induced by other endocrinologic disorders.
* Change in body weight \> 5 kg within last 90 days.
* Previous or planned surgical, endoscopic, or device-based treatment for obesity.
* History of malignancy within the past 5 years.
* Type 1 or Type 2 diabetes mellitus.
* History of chronic pancreatitis or history of acute pancreatitis within last 180 days.
* Family or personal history of medullary thyroid cancer.
* Previous participation in a Maridebart Cafraglutide trial.
Study design
Enrollment target: 230 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-10-15
Estimated completion: 2027-09-08
Last updated: 2026-11-09
Interventions
Drug: Maridebart cafraglutideDevice: Autoinjector
Primary outcomes
- • Percentage of Participants Who Successfully Self-inject a Full Dose Among Those Who Attempted Injection at Each Home Administration (Weeks 12, 16, and 20)
- • Percentage of Participants Who Successfully Self-inject a Full Dose Among All Participants Who Entered the Home Self-administration Phase at Each Scheduled Home Administration (Weeks 12, 16, and 20)
Sponsor
Amgen · industry
Contacts & investigators
ContactAmgen Call Center · contact · medinfo@amgen.com · 866-572-6436
InvestigatorMD · study_director, Amgen
All locations (25)
Apex Clinical ResearchRecruiting
San Diego, California, United States
Southern Clinical ResearchRecruiting
Miami, Florida, United States
Research Institute of South FloridaRecruiting
Miami, Florida, United States
Clinical Neuroscience Solutions LLCRecruiting
Orlando, Florida, United States
Florida Institute for Clinical ResearchRecruiting
Orlando, Florida, United States
Charter Research - The VillagesRecruiting
The Villages, Florida, United States
Nsc ResearchRecruiting
Johns Creek, Georgia, United States
North Georgia Clinical ResearchRecruiting
Woodstock, Georgia, United States
Solaris Clinical ResearchRecruiting
Meridian, Idaho, United States
Alliance For Multispecialty Research - Oak BrookRecruiting
Oak Brook, Illinois, United States
Flourish ResearchRecruiting
Bowie, Maryland, United States
Rochester Clinical ResearchRecruiting
Rochester, New York, United States
Centricity ResearchRecruiting
Morehead City, North Carolina, United States
Centricity Research DublinRecruiting
Columbus, Ohio, United States
Epic Medical Research - OklahomaRecruiting
Chickasha, Oklahoma, United States
Tribe Clinical Research LLC Dba Mountain View Clinical ResearchRecruiting
Greenville, South Carolina, United States
Cedar Health Research- Texas Native HealthRecruiting
Dallas, Texas, United States
Cedar Health Research, LLCRecruiting
Dallas, Texas, United States
Soma Clinical Trials, LLCRecruiting
Denison, Texas, United States
Epic Medical Research - Red OakRecruiting
DeSoto, Texas, United States
Biopharma Informatic, LLCRecruiting
Houston, Texas, United States
Research Physicians Network LLCRecruiting
Houston, Texas, United States
Texas Institute of CardiologyRecruiting
McKinney, Texas, United States
North Hills Medical ResearchRecruiting
North Richland Hills, Texas, United States
Latin Clinical Trial CenterRecruiting
San Juan, Puerto Rico